120 related articles for article (PubMed ID: 96523)
1. Interrelationships between blood volume, venous haematocrit and renal failure in myelomatosis.
Hansen OP; Drivsholm A
Scand J Haematol; 1978 May; 20(5):461-6. PubMed ID: 96523
[No Abstract] [Full Text] [Related]
2. Serum erythropoietin in myelomatosis.
Hansen OP; Thorling EB; Drivsholm A
Scand J Haematol; 1977 Jul; 19(1):106-10. PubMed ID: 882835
[TBL] [Abstract][Full Text] [Related]
3. Anaemia in patients with myelomatosis.
Ting WC; Cavill I; Jacobs A; Kaaba S; May A; Smith S; Whittaker JA
Br J Cancer; 1982 Jun; 45(6):887-94. PubMed ID: 7093123
[TBL] [Abstract][Full Text] [Related]
4. Chronic hemodialysis in myelomatosis.
Leech SH; Polesky HF; Shapiro FL
Ann Intern Med; 1972 Aug; 77(2):239-42. PubMed ID: 4641657
[No Abstract] [Full Text] [Related]
5. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
[TBL] [Abstract][Full Text] [Related]
6. Renal insufficiency in multiple myeloma: basic mechanisms in its development and methods for treatment.
Abdulkadyrov KM; Bessmeltsev SS
Ren Fail; 1996 Jan; 18(1):139-46. PubMed ID: 8820511
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of erythropoiesis in myelomatosis.
Birgens HS; Hansen OP; Henriksen JH; Wantzin P
Scand J Haematol; 1979 Apr; 22(4):357-63. PubMed ID: 472659
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
Popat R; Plesner T; Davies F; Cook G; Cook M; Elliott P; Jacobson E; Gumbleton T; Oakervee H; Cavenagh J
Br J Haematol; 2013 Mar; 160(5):714-7. PubMed ID: 23205612
[No Abstract] [Full Text] [Related]
9. [Renal insufficiency in myelomatosis. Prognostic factors and survival].
Gregersen H; Ibsen JS; Nielsen M
Ugeskr Laeger; 1997 May; 159(22):3387-92. PubMed ID: 9199025
[TBL] [Abstract][Full Text] [Related]
10. Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease.
Musolino C; Allegra A; Profita M; Alonci A; Saitta S; Russo S; Bonanno A; Innao V; Gangemi S
Br J Haematol; 2013 Mar; 160(5):709-10. PubMed ID: 23205532
[No Abstract] [Full Text] [Related]
11. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?
Terpos E; Christoulas D; Kastritis E; Katodritou E; Pouli A; Michalis E; Papassotiriou I; Dimopoulos MA;
Eur J Haematol; 2013 Oct; 91(4):347-55. PubMed ID: 23829647
[TBL] [Abstract][Full Text] [Related]
12. Assessment of glomerular filtration rate in dogs with renal insufficiency: analysis of the 51Cr-EDTA clearance and its relation to the plasma concentrations of urea and creatinine.
Biewenga WJ; van den Brom WE
Res Vet Sci; 1981 Mar; 30(2):158-60. PubMed ID: 6789422
[TBL] [Abstract][Full Text] [Related]
13. Changes in red cell mass, plasma volume and haematocrit in patients on continuous ambulatory peritoneal dialysis.
de Paepe M; Lameire N; Schelstraete K; Ringoir S
Proc Eur Dial Transplant Assoc; 1981; 18():286-9. PubMed ID: 7329973
[No Abstract] [Full Text] [Related]
14. Influence of renal insufficiency on levels of serum ribonuclease in patients with multiple myeloma.
Karpetsky TP; Humphrey RL; Levy CC
J Natl Cancer Inst; 1977 Apr; 58(4):875-80. PubMed ID: 845991
[TBL] [Abstract][Full Text] [Related]
15. Haematocrit and the risk of developing end-stage renal disease.
Iseki K; Ikemiya Y; Iseki C; Takishita S
Nephrol Dial Transplant; 2003 May; 18(5):899-905. PubMed ID: 12686662
[TBL] [Abstract][Full Text] [Related]
16. The effect of low molecular weight dextran on the viscosity and suspension characteristics of blood.
Eisenberg S
Am J Med Sci; 1969 May; 257(5):336-43. PubMed ID: 5795738
[No Abstract] [Full Text] [Related]
17. Blood volume and hematocrit value in macroglobulinemia and myeloma.
Kopp WL; MacKinney AA; Wasson G
Arch Intern Med; 1969 Apr; 123(4):394-6. PubMed ID: 4976452
[No Abstract] [Full Text] [Related]
18. [Evaluation of the prognostic significance of renal insufficiency in myeloma. Multivariate analysis].
López Pascual J; García Ahumada F; Fernández Rañada JM
Med Clin (Barc); 1987 Nov; 89(16):678-80. PubMed ID: 3695698
[No Abstract] [Full Text] [Related]
19. Younger age of presentation and extraosseous tumour in IgD myelomatosis.
Hobbs JR; Corbett AA
Br Med J; 1969 Feb; 1(5641):412-4. PubMed ID: 4179168
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of methods for evaluating renal function (Data of Kaunas University of Medicine Hospital in 2006)].
Kuzminskis V; Skarupskiene I; Bumblyte IA; Kardauskaite Z; Uogintaite J
Medicina (Kaunas); 2007; 43 Suppl 1():46-51. PubMed ID: 17551276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
